{"title":"肝脏恶性肿瘤中钬-166标记羟基磷灰石颗粒的动物辐射吸收剂量评价。","authors":"Reza Bagheri, Hassan Ranjbar","doi":"10.22038/aojnmb.2024.79679.1560","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. Intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.</p><p><strong>Methods: </strong>In this work, the radiation absorbed dose of <sup>166</sup>Ho-hydroxyapatite (<sup>166</sup>Ho-HA) radiopharmaceutical was estimated for adult men based on biodistribution data in normal Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied.</p><p><strong>Results: </strong>The results show that more than 84% of the absorbed dose is localized in liver tissue (7.35 mGy MBq<sup>-1</sup>). Also, radiation absorbed doses of <sup>166</sup>Ho-HA for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about 0.18, 0.38, and 0.24 mGy MBq<sup>-1</sup>, respectively. The maximum administrated activity was obtained at 87.5 MBq kg<sup>-1</sup> of body weight with an effective dose of 0.39 mSv MBq<sup>-1</sup>. The maximum tolerable dose (MTD) for liver tissue was 6.13 GBq (165.56 mCi).</p><p><strong>Conclusion: </strong>This study indicated that <sup>166</sup>Ho-HA can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.</p>","PeriodicalId":8503,"journal":{"name":"Asia Oceania Journal of Nuclear Medicine and Biology","volume":"13 1","pages":"94-101"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682468/pdf/","citationCount":"0","resultStr":"{\"title\":\"Animal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies.\",\"authors\":\"Reza Bagheri, Hassan Ranjbar\",\"doi\":\"10.22038/aojnmb.2024.79679.1560\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. Intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.</p><p><strong>Methods: </strong>In this work, the radiation absorbed dose of <sup>166</sup>Ho-hydroxyapatite (<sup>166</sup>Ho-HA) radiopharmaceutical was estimated for adult men based on biodistribution data in normal Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied.</p><p><strong>Results: </strong>The results show that more than 84% of the absorbed dose is localized in liver tissue (7.35 mGy MBq<sup>-1</sup>). Also, radiation absorbed doses of <sup>166</sup>Ho-HA for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about 0.18, 0.38, and 0.24 mGy MBq<sup>-1</sup>, respectively. The maximum administrated activity was obtained at 87.5 MBq kg<sup>-1</sup> of body weight with an effective dose of 0.39 mSv MBq<sup>-1</sup>. The maximum tolerable dose (MTD) for liver tissue was 6.13 GBq (165.56 mCi).</p><p><strong>Conclusion: </strong>This study indicated that <sup>166</sup>Ho-HA can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.</p>\",\"PeriodicalId\":8503,\"journal\":{\"name\":\"Asia Oceania Journal of Nuclear Medicine and Biology\",\"volume\":\"13 1\",\"pages\":\"94-101\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682468/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia Oceania Journal of Nuclear Medicine and Biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22038/aojnmb.2024.79679.1560\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Oceania Journal of Nuclear Medicine and Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/aojnmb.2024.79679.1560","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Animal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies.
Objectives: Liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. Intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.
Methods: In this work, the radiation absorbed dose of 166Ho-hydroxyapatite (166Ho-HA) radiopharmaceutical was estimated for adult men based on biodistribution data in normal Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied.
Results: The results show that more than 84% of the absorbed dose is localized in liver tissue (7.35 mGy MBq-1). Also, radiation absorbed doses of 166Ho-HA for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about 0.18, 0.38, and 0.24 mGy MBq-1, respectively. The maximum administrated activity was obtained at 87.5 MBq kg-1 of body weight with an effective dose of 0.39 mSv MBq-1. The maximum tolerable dose (MTD) for liver tissue was 6.13 GBq (165.56 mCi).
Conclusion: This study indicated that 166Ho-HA can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
